StockNews.com assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a research report report published on Saturday morning. The firm issued a sell rating on the stock.
iBio Price Performance
Shares of IBIO opened at $1.91 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91. iBio has a twelve month low of $1.02 and a twelve month high of $26.20.
iBio (NYSE:IBIO – Get Free Report) last released its earnings results on Friday, February 9th. The company reported ($2.42) earnings per share for the quarter.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Featured Articles
- Five stocks we like better than iBio
- What Are Growth Stocks and Investing in Them
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Invest in Biotech Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What Are the U.K. Market Holidays? How to Invest and Trade
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.